Differences in Shear Stress, Residence Time and Estimates of Hemolysis Between Different Ventricular Assist Devices

2011 ◽  
Author(s):  
Katharine H. Fraser ◽  
Tao Zhang ◽  
Bartley P. Griffith ◽  
Zhongjun J. Wu
Keyword(s):  
Cardiovascular Disease ◽  
Mechanical Circulatory Support ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Ventricular Assist ◽  
The Past ◽  
The Us ◽  
Mechanical Circulatory Support Devices ◽  
End Stage ◽  
Support Devices

Cardiovascular disease is the leading cause of mortality globally. Among various forms of cardiovascular disease, heart failure (HF) affects 5.7 million patients in the United States1. Despite optimal treatment, some patients still do not improve and the available therapies fail to control their symptoms; for them, cardiac transplantation may be the only option. However, only around 2200 transplants are performed in the US each year1, or only about 6% of the estimated 35,000 US patients who would benefit actually receive a heart. To address the need to support the circulation in patients with end-stage HF a wide variety of mechanical circulatory support devices (MCSDs) have been developed over the past four decades.

Development of Mechanical Circulatory Support Devices: 55 Years and Counting

2021 ◽  
Vol 32 (4) ◽  
pp. 424-433
Author(s):  
Emalie Petersen
Keyword(s):  
Mechanical Circulatory Support ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Left Ventricular Assist ◽  
Mechanical Circulatory Support Devices ◽  
Support Devices

Heart failure is a leading cause of morbidity and mortality in the United States. Treatment of this condition increasingly involves mechanical circulatory support devices. Even with optimal medical therapy and use of simple cardiac devices, heart failure often leads to reduced quality of life and a shortened life span, prompting exploration of more advanced treatment approaches. Left ventricular assist devices constitute an effective alternative to cardiac transplantation. These devices are not without complications, however, and their use requires careful cooperative management by the patient’s cardiology team and primary care provider. Left ventricular assist devices have undergone many technological advancements since they were first introduced, and they will continue to evolve. This article reviews the history of different types of left ventricular assist devices, appropriate patient selection, and common complications in order to increase health professionals’ familiarity with these treatment options.

scholarly journals Haemolysis induced by mechanical circulatory support devices: unsolved problems

Perfusion ◽  
2020 ◽  
Vol 35 (6) ◽  
pp. 474-483
Author(s):  
Inge Köhne
Keyword(s):  
Shear Stress ◽  
Continuous Flow ◽  
Mechanical Circulatory Support ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Ventricular Assist ◽  
Theoretical Approaches ◽  
Blood Pumps ◽  
Mechanical Circulatory Support Devices ◽  
Support Devices

Since the use of continuous flow blood pumps as ventricular assist devices is standard, the problems with haemolysis have increased. It is mainly induced by shear stress affecting the erythrocyte membrane. There are many investigations about haemolysis in laminar and turbulent blood flow. The results defined as threshold levels for the damage of erythrocytes depend on the exposure time of the shear stress, but they are very different, depending on the used experimental methods or the calculation strategy. Here, the results are resumed and shown in curves. Different models for the calculation of the strengths of erythrocytes are discussed. There are few results reported about tests of haemolysis in blood pumps, but some theoretical approaches for the design of continuous flow blood pumps according to low haemolysis have been investigated within the last years.

Use of Mechanical Circulatory Support Devices in End-Stage Heart Failure Patients

2014 ◽  
Vol 29 (5) ◽  
pp. 717-722 ◽  
Author(s):  
Antonio Loforte ◽  
Francesco Musumeci ◽  
Andrea Montalto ◽  
Emanuele Pilato ◽  
Paola Lilla Della Monica ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Heart Failure Patients ◽  
Mechanical Circulatory Support Devices ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Support Devices

The Effect of Impeller Position on CFD Calculations of Blood Flow in Magnetically Levitated Centrifugal Blood Pumps

2010 ◽  
Author(s):  
Katharine H. Fraser ◽  
M. Ertan Taskin ◽  
Tao Zhang ◽  
J. Scott Richardson ◽  
Barry Gellman ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
The United States ◽  
Lifestyle Changes ◽  
Circulatory Support ◽  
Ventricular Assist ◽  
Bridge To Transplant ◽  
Mechanical Circulatory Support Devices ◽  
The Right ◽  
End Stage ◽  
Transcatheter Interventions

Cardiovascular disease is the leading cause of mortality globally. Among various forms of cardiovascular disease, heart failure (HF) affects 5.7 million patients in the United States with about 670,000 new patients diagnosed for the first time annually (1). The fatality rate for HF is high, with one in five people dying within 1 year (1). The number of deaths has increased (1) despite advances in surgical treatment and new pharmaceutical therapies. Many therapies are available to treat patients with HF, including lifestyle changes, medications, transcatheter interventions and surgery. However, despite optimal medical and surgical therapies, some patients still do not improve and the available therapies fail to control their symptoms; for them, cardiac transplantation may be the only treatment option. However, only approximately 2300 donor hearts become available each year resulting in around 2200 transplants (1), or only about 6% of the estimated 35,000 US patients who would benefit from a heart actually receiving a transplant. To address the need to support the circulation in patients with end-stage HF a wide variety of mechanical circulatory support devices (MCSDs) have been developed over the past four decades. These MCSDs have been developed as a bridge to transplant, a bridge to recovery, and as an end stage treatment. They can be implanted as a ventricular assist device (VAD) to support the left ventricle (LVAD) or the right ventricle (RVAD) or two devices are used to support both left and right ventricles (Bi-VAD).

Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3

2018 ◽  
Vol 53 (4) ◽  
pp. 430-433
Author(s):  
Alana M. Ciolek ◽  
Audrey J. Littlefield ◽  
Douglas L. Jennings
Keyword(s):  
Mechanical Circulatory Support ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
End Stage ◽  
Brighter Future

Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy.

Sign in / Sign up

Export Citation Format

Share Document